Changes

'''Organogenesis ''' is a corporation based in Canton, MA.<ref name='Organogenesis 2010'>{{cite webREFweb |quote=The corporate headquarters and manufacturing facility are located in Canton, Massachusetts. |last= |first= |publisher=Organogenesis |date=2010 |title=Headquarters | url = http://www.organogenesis.com/about_us/headquarters.html | title = Headquarters | accessdate = 2011-03-06 | publisher = Organogenesis | quote = The corporate headquarters and manufacturing facility are located in Canton, Massachusetts.}}</ref> They profit from [[Apligraf]], which is a synthetic [[skin ]] created from harvested foreskins.<ref name='Organogenesis 20102011'>{{cite webREFweb |quote=Human keratinocytes and fibroblasts are derived from neonatal foreskins. |last= |first= |publisher=Organogenesis |date=2011 |title=Apligraf: How Is It Made? | url = http://www.apligraf.com/professional/what_is_apligraf/how_is_it_made/ | title = Apligraf: How Is It Made? | accessdate = 2011-03-06 | publisher = Organogenesis | quote = Human keratinocytes and fibroblasts are derived from neonatal foreskins

 ==Call for increase of foreskin harvesting== {{Quote boxCitation |title Title= We Must Be Able To Obtain Adequate Sources Of Supply |quote Text= We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant [[foreskin]], they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the [[HIV ]] or "[[AIDS]]" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products. |source Author= |Source=Organogensis |lang= |before= |after= |Transcription= -- |Translation= |ref=<ref>[http://sec.edgar-online.com/organogenesis-inc/10-k-annual-report/2001/04/02/Section2.aspx Organogensis, 2001 Annual Report (Delaware: Organogenesis, 2001), p.8.] |align = center |width = 50% |quoted = yes</ref>

==Apligraph Oral==Organogenesis is presently seeking [[FDA]] approval for Apligraph Oral, a [[foreskin]]-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFweb |last= |first= |date=2011-11-17 |title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript |url=https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-september-2-3-2021-meeting-announcement |publisher= |accessdate=2021-09-02}}</ref>

Organogenesis is presently seeking FDA approval for Apligraph Oral, a foreskin-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref> {{cite web | url = http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf | title = November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript | accessdate = 2011-12-20 | date = November 2011REF}}</ref>

[[Category:OrganizationsFrom CircLeaks]][[Category:CircLeaksFrom IntactWiki]]

[[Categoryde:From IntactWiki]][[Category:Construction Site{{FULLPAGENAME}}]]